Whitehawk Therapeutics (WHWK) Insider Zhao Buys 38,040 Shares

Baiteng Zhao recently added 38,040 shares of WHWK to his portfolio on June 12, 2026. The transaction did not specify a purchase price, but WHWK shares are currently trading around $4.16.

Other Institutional Activity in WHWK

Several institutional investors maintain significant holdings in WHWK. QVT Financial LP holds 4,615,709 shares valued at about $15.9 million. Similarly, Orbimed Advisors LLC has 4,166,000 shares worth approximately $14.4 million. Suvretta Capital Management, LLC owns 3,700,000 shares valued at $12.8 million, while Acuta Capital Partners, LLC holds 3,410,402 shares totaling $11.8 million. Lastly, Avoro Capital Advisors LLC possesses 2,849,402 shares worth nearly $9.8 million.

Whitehawk Therapeutics, Inc. Stock Down 1.0%

Shares of WHWK trade near $4.16. The stock's recent activity is supported by substantial institutional holdings, indicating a level of interest from major investors.

Insider Buying and Selling at Whitehawk Therapeutics, Inc.

On June 12, 2026, multiple insiders including Castelein Caley, Desai Neil, Reeve Emma, Maroun Richard, Zhao Baiteng, and Aghazadeh Behzad each purchased 38,040 shares of WHWK. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On April 16, 2026, Citizens initiated coverage on WHWK with a 'buy' rating and a price target of $8. Previously, on December 22, 2025, Jones Trading also initiated coverage with a 'buy' rating and a $7 price target. The consensus among analysts is positive, with a general recommendation to buy.

Bottom Line

The recent insider buying activity at WHWK, including Baiteng Zhao's acquisition, highlights interest in the company. With WHWK shares trading at $4.16 and analysts setting higher price targets, investors are paying close attention. It's important to remember that filings such as these are backward-looking and may not reflect the current position.